Advertisement

Multicentre Trial on Gangliosides in Diabetic Peripheral Neuropathy

  • Domenico Fedele
  • Gaetano Crepaldi
  • Leontino Battistin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 174)

Abstract

In spite of the reports on the therapy with pyridoxine, aldose reductase inhibitors,2–4 and myoinositol, 5,6; at present no specific treatment is available for diabetic peripheral neuropathy, the most frequent long-term complication of diabetes mellitus.

Keywords

Peripheral Neuropathy Diabetic Neuropathy Ulnar Nerve Diabetic Peripheral Neuropathy Aldose Reductase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E. R. Levin, T. A. Hanscom, M. Fisher, W. A. Laustad, A. Lui, A. Ryan, D. Glokner, and S. R. Levin, The influence of pyridoxine in diabetic peripheral neuropathy, Diabetes Care 4:606 (1981).PubMedCrossRefGoogle Scholar
  2. 2.
    K. H. Gabbay, N. Spack, S. Loo, J. L. Hirsh, and A. A. Ackil, Aldose reductase inhibition: studies with alrestatin, Metabolism 28(Suppl):471 (1979).PubMedCrossRefGoogle Scholar
  3. 3.
    A. Culebras, J. Alio, and J. L. Herrera, Effect of aldose reductase inhibitor on diabetic peripheral neuropathy, Arch. Neurol. 38:133 (1981).PubMedCrossRefGoogle Scholar
  4. 4.
    R. G. Judzerwitsch, J. B. Jaspan, K. S. Polonsky et al., Aldose reductase inhibition improves nerve conduction velocity in diabetic patients, New Engl. J. Med. 308:119 (1983).CrossRefGoogle Scholar
  5. 5.
    D. A. Greene, P. V. De Jesus, and A. I. Winegrad, Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes, J. Clin. Invest. 55:1326 (1975).PubMedCrossRefGoogle Scholar
  6. 6.
    R. S. Clements, Jr., B. Vaurganti, T. Kuba, S. J. Oh, and B. Darnell, Dietary myoinositol intake and peripheral nerve function in diabetic neuropathy, Metabolism 28:477 (1979).PubMedCrossRefGoogle Scholar
  7. 7.
    A. Mingione, M. Monteleone, G. Paruzzi, O. Soragni, G. Cristiani, C. Moretti, W. Mega, and F. Scanabissi, Research in the cerebral gangliosides in neurolyses of the upper limb, Clin. Neurophysiol. 19:353 (1979).Google Scholar
  8. 8.
    S. Bassi, M. G. Albizzati, and L. Frattola, Electromyographic study of diabetic and alcoholic Polyneuropathic patients treated with gangliosides, Muscle & Nerve 5:351 (1982).CrossRefGoogle Scholar
  9. 9.
    B. Ceccarelli, F. Aporti, and M. Finesso, Effects of brain gangliosides on functional recovery in experimental regeneration and reinnervation, in: “Ganglioside Function,” G. Porcellati, B. Ceccarelli, and G. Tettamanti, eds., Plenum Press, New York and London (1976).Google Scholar
  10. 10.
    A. Gorio, G. Carmignoto, L. Facci, and M. Finesso, Motor nerve sprouting induced by gangliosides treatment. Possible indications for gangliosides on neuronal growth, Brain Res. 197:236 (1980).PubMedCrossRefGoogle Scholar
  11. 11.
    A. Gorio, G. Carmignoto, and G. Ferrari, Axon sprouting stimulated by gangliosides. A new model for elongation and sprouting, in: “Gangliosides in Neurological and Neuromuscular Function, Development and Repair,” M. M. Rapport and A. Gorio, eds., Raven Press, New York (1981).Google Scholar
  12. 12.
    F. Norido, R. Canella, and F. Aporti, Acceleration of nerve regeneration by gangliosides estimated by the somatosensory evoked potentials, Experientia (Basel) 37:301 (1981).CrossRefGoogle Scholar
  13. 13.
    A. Gorio, P. Marini, and R. Zanoni, Muscle reinnervation III. Motoneuron sprouting capacity, enhancement by exogenous gangliosides, Neuroscience 8:417 (1983).PubMedCrossRefGoogle Scholar
  14. 14.
    A. Gorio, F. Aporti, and F. Norido, Ganglioside treatment in experimental diabetic neuropathy, in: “Gangliosides in Neurological and Neuromuscular Function, Development and Repair,” M. M. Rapport and A. Gorio, eds., Raven Press, New York (1981).Google Scholar
  15. 15.
    A. Gorio, G. Carmignoto, G. Ferrari, F. Norido, M. G. Nunzi, R. Rubini, and R. Zanoni, Pharmacological aspects of experimental peripheral neuropathy, in: “International Conference on Peripheral Neuropathies,” S. Refsum, C. L. Bolis, and Portera-Sanchez, eds., Excerpta Medica, Amsterdam, Oxford-Princeton (1982).Google Scholar
  16. 16.
    F. Norido, R. Canella, and A. Gorio, Ganglioside treatment of neuropathy in diabetic mice, Muscle & Nerve 5:107 (1982).CrossRefGoogle Scholar
  17. 17.
    G. Pozza, V. Saibene, G. Comi, and N. Canal, The effect of ganglioside administration in human diabetic peripheral neuropathy, in: “Gangliosides in Neurological and Neuromuscular Function, Development and Repair,” M. M. Rapport and A. Gorio, eds., Raven Press, New York (1981).Google Scholar
  18. 18.
    J. W. Daly, The effect of gangliosides on activity of adenylate cyclase and phosphodiesterase from rat cerebral cortex, in: “Gangliosides in Neurological and Neuromuscular Function, Development and Repair,” M. M. Rapport and A. Gorio, eds., Raven Press, New York (1981).Google Scholar
  19. 19.
    A. Leon, L. Facci, G. Toffano, S. Sonnino, and G. Tettamanti, Activation of (Na+K+)ATPase by nanomolar concentrations of GM1 ganglioside, J. Neurochem. 37:350 (1981).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Domenico Fedele
    • 1
  • Gaetano Crepaldi
    • 1
  • Leontino Battistin
    • 2
  1. 1.Institute of Internal MedicineUniversity of PadovaItaly
  2. 2.Institute of NeurologyUniversity of PadovaItaly

Personalised recommendations